Role of vitamin K2 in preventing the recurrence of hepatocellular carcinoma after curative treatment: A meta-analysis of randomized controlled trials

BMC Gastroenterology

Volumn 12, Issue , 2012, Pages

  Riaz, Irbaz Bin ^a   Riaz, Haris ^b   Riaz, Talha ^b   Rahman, Sophia ^c   Amir, Muhammad ^d   Badshah, Maaz B ^e   Kazi, Abdul Nafey ^b  

^a UNIVERSITY OF ARIZONA   (United States)

^b DOW UNIVERSITY OF HEALTH SCIENCES   (Pakistan)

^c NEW YORK METHODIST HOSPITAL   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FARNOQUINONE; MENATETRENONE; PERINDOPRIL; PLACEBO;

ARTICLE; CANCER SURVIVAL; COCHRANE LIBRARY; DATA ANALYSIS; DRUG DOSE COMPARISON; DRUG EFFICACY; EMBASE; HUMAN; LIVER CELL CARCINOMA; LIVER RESECTION; MEDLINE; META ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; RECURRENCE RISK; RECURRENT CANCER; RISK ASSESSMENT; SYSTEMATIC REVIEW; TUMOR ABLATION;

CARCINOMA, HEPATOCELLULAR; CHEMOPREVENTION; CONFIDENCE INTERVALS; DISEASE-FREE SURVIVAL; HUMANS; LIVER NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VITAMIN K 2; VITAMINS;

EID: 84870058151     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-12-170     Document Type: Article

References (20)

1. Yoshida H, Shiratori Y, Kudo M, Shiina S, Mizuta T, Kojiro M, et al. Effect of vitamin K2 on the recurrence of hepatocellular carcinoma. Hepatology 2011, 54(2):532-540. 10.1002/hep.24430, 21574174.
2. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008, 48(Supplement 1(0)):S20-S37.
3. Kakizaki S, Sohara N, Sato K, Suzuki H, Yanagisawa M, Nakajima H, et al. Preventive effects of vitamin K on recurrent disease in patients with hepatocellular carcinoma arising from hepatitis C viral infection. J Gastroenterol Hepatol 2007, 22(4):518-522. 10.1111/j.1440-1746.2007.04844.x, 17376044.
4. Yoshiji H, Noguchi R, Toyohara M, Ikenaka Y, Kitade M, Kaji K, et al. Combination of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates cumulative recurrence of hepatocellular carcinoma. J Hepatol 2009, 51(2):315-321. 10.1016/j.jhep.2009.04.011, 19501932.
5. Ikeda K, Arase Y, Saitoh S, Kobayashi M, Suzuki Y, Suzuki F, et al. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-a prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 2000, 32(2):228-232. 10.1053/jhep.2000.9409, 10915728.
6. Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Kinoshita H. Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy. Br J Surg 2002, 89(4):418-422. 10.1046/j.0007-1323.2001.02054.x, 11952580.
7. Kudo M, Sakaguchi Y, Chung H, Hatanaka K, Hagiwara S, Ishikawa E, et al. Long-Term Interferon Maintenance Therapy Improves Survival in Patients with HCV-Related Hepatocellular Carcinoma after Curative Radiofrequency Ablation. Oncology 2007, 72(Suppl. 1):132-138.
8. Shiratori Y, Shiina S, Teratani T, Imamura M, Obi S, Sato S, et al. Interferon Therapy after Tumor Ablation Improves Prognosis in Patients with Hepatocellular Carcinoma Associated with Hepatitis C Virus. Ann Intern Med 2003, 138(4):299-306. 2003 February 18.
9. Saaristo A, Karpanen T, Alitalo K. Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis. Oncogene 2000, 19(53):6122-6129. 10.1038/sj.onc.1203969, 11156525.
10. Yoshiji H, Kuriyama S, Yoshii J, Yamazaki M, Kikukawa M, Tsujinoue H, et al. Vascular endothelial growth factor tightly regulates in vivo development of murine hepatocellular carcinoma cells. Hepatology 1998, 28(6):1489-1496. 10.1002/hep.510280607, 9828211.
11. Eskens FALM, Verweij J. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; A review. Eur J Cancer 2006, 42(18):3127-3139. 10.1016/j.ejca.2006.09.015, 17098419.
12. Verheul HMW, Pinedo HM. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 2007, 7(6):475-485. 10.1038/nrc2152, 17522716.
13. Lian JB, Friedman PA. The vitamin K-dependent synthesis of gamma-carboxyglutamic acid by bone microsomes. J Biol Chem 1978, 253(19):6623-6626. 1978 October 10.
14. Mizuta T, Ozaki I. Hepatocellular Carcinoma and Vitamin K. Vitamins & Hormones 2008, 435-442. Academic Press, Gerald L.
15. Mizuta T, Ozaki I, Eguchi Y, Yasutake T, Kawazoe S, Fujimoto K, et al. The effect of menatetrenone, a vitamin K2 analog, on disease recurrence and survival in patients with hepatocellular carcinoma after curative treatment. Cancer 2006, 106(4):867-872. 10.1002/cncr.21667, 16400650.
16. Verhagen AP, de Vet HCW, de Bie RA, Kessels AGH, Boers M, Bouter LM, et al. The Delphi List: A Criteria List for Quality Assessment of Randomized Clinical Trials for Conducting Systematic Reviews Developed by Delphi Consensus. J Clin Epidemiol 1998, 51(12):1235-1241. 10.1016/S0895-4356(98)00131-0, 10086815.
17. Hotta N, Ayada M, Sato K, Ishikawa T, Okumura A, Matsumoto E, et al. Effect of vitamin K2 on the recurrence in patients with hepatocellular carcinoma. Hepatogastroenterology 2007, 54(79):2073-2077. [Randomized Controlled Trial].
18. Chu K-J, Lai ECH, Yao X-P, Zhang H-W, Lau WY, Fu X-H, et al. Vitamin Analogues in Chemoprevention of Hepatocellular Carcinoma After Resection or Ablation-A Systematic Review and Meta-analysis. Asian J Surg 2010, 33(3):120-126. 10.1016/S1015-9584(10)60021-8, 21163409.
19. Matsumoto K, Okano J-I, Nagahara T, Murawaki Y. Apoptosis of liver cancer cells by vitamin K2 and enhancement by MEK inhibition. Int J Oncol 2006 Dec, 29(6):1501-1508.
20. Ozaki I, Zhang H, Mizuta T, Ide Y, Eguchi Y, Yasutake T, et al. Menatetrenone, a vitamin K2 analogue, inhibits hepatocellular carcinoma cell growth by suppressing cyclin D1 expression through inhibition of nuclear factor kappaB activation. Clin Cancer Res 2007 Apr 1, 13(7):2236-2245.